Abstract
Hyperkalemic periodic paralysis (HyperKPP) is a disease characterized by periods of myotonic discharges and paralytic attacks causing weakness, the latter associated with increases in plasma [K+]. The myotonic discharge is due to increased Na+ influx through defective Na+ channels that triggers generation of several action potentials. The subsequent increase in extracellular K+ concentration causes excessive membrane depolarization that inactivates Na+ channels triggering the paralysis. None of the available treatments is fully effective. This paper reviews the capacity of Na+ K+ ATPase pumps, KATP and ClC-1 Cl- channels in improving membrane excitability during muscle activity and how using these three membrane components we can study future and more effective treatments for HyperKPP patients. The review of current patents related to HyperKPP reinforces the need of novel approaches for the treatment of this channelopathy.
Keywords: Skeletal muscle, muscle fatigue, muscle paralysis, hyperkalemic periodic paralysis, patients, humans, treatments, pain, muscle soreness, muscle spasms, muscle weakness, potassium, plasma potassium levels, Na+/K+ ATPase pumps, patents
Recent Patents on Biotechnology
Title:Lessons Learned from Muscle Fatigue: Implications for Treatment of Patients with Hyperkalemic Periodic Paralysis
Volume: 6 Issue: 3
Author(s): Jean-Marc Renaud and Lawrence J. Hayward
Affiliation:
Keywords: Skeletal muscle, muscle fatigue, muscle paralysis, hyperkalemic periodic paralysis, patients, humans, treatments, pain, muscle soreness, muscle spasms, muscle weakness, potassium, plasma potassium levels, Na+/K+ ATPase pumps, patents
Abstract: Hyperkalemic periodic paralysis (HyperKPP) is a disease characterized by periods of myotonic discharges and paralytic attacks causing weakness, the latter associated with increases in plasma [K+]. The myotonic discharge is due to increased Na+ influx through defective Na+ channels that triggers generation of several action potentials. The subsequent increase in extracellular K+ concentration causes excessive membrane depolarization that inactivates Na+ channels triggering the paralysis. None of the available treatments is fully effective. This paper reviews the capacity of Na+ K+ ATPase pumps, KATP and ClC-1 Cl- channels in improving membrane excitability during muscle activity and how using these three membrane components we can study future and more effective treatments for HyperKPP patients. The review of current patents related to HyperKPP reinforces the need of novel approaches for the treatment of this channelopathy.
Export Options
About this article
Cite this article as:
Renaud Jean-Marc and J. Hayward Lawrence, Lessons Learned from Muscle Fatigue: Implications for Treatment of Patients with Hyperkalemic Periodic Paralysis, Recent Patents on Biotechnology 2012; 6 (3) . https://dx.doi.org/10.2174/1872208311206030184
DOI https://dx.doi.org/10.2174/1872208311206030184 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Laterality of Brain Activation for Risk Factors of Addiction
Current Drug Abuse Reviews Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS)
Current Medicinal Chemistry Clozapine Safety, 40 Years Later
Current Drug Safety Approaches to Mitochondrial Gene Therapy
Current Gene Therapy A Genetic Dissection of Antipsychotic Induced Movement Disorders
Current Medicinal Chemistry Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy ABC Transporters and the Blood-Brain Barrier
Current Pharmaceutical Design Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design <i>In Vitro</i> Antioxidant and Anti-Convulsant Activity of Methanolic Extract of <i>Sarasvata churna</i> Using scPTZ and MES Models
The Natural Products Journal The Effects of Aqueous Extract of Apium Graveolens on Brain Tissues Oxidative Damage in Pentylenetetrazole-induced Seizures Model in Rat
Current Nutrition & Food Science 9th International Meeting on Metabotropic Gglutamate Receptors (Taormina, Sicily, October 1-6, 2017).
Current Neuropharmacology Therapeutic Trials in Human Transmissible Spongiform Encephalopathies: Recent Advances and Problems to Address
Infectious Disorders - Drug Targets Neuroprotective Role of Agmatine in Neurological Diseases
Current Neuropharmacology A New Class of Anticonvulsants Possessing 6 Hz Psychomotor Seizure Test Activity: 2-(1H-Benzotriazol-1-yl)-N'-[Substituted] Acetohydrazides
Medicinal Chemistry An Overview of the Selectivity and Efficiency of the Bacterial Carbonic Anhydrase Inhibitors
Current Medicinal Chemistry Are Antipsychotics Useful in the Treatment of Anorexia Nervosa? A Review of the Literature
Current Psychopharmacology FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI Subjects
Current Radiopharmaceuticals Is There Any Scientific Basis of Hawan to be Used in the Alzheimer’s Disease Prevention/Cure?
Current Traditional Medicine Biomedical Application of Polymers: A Case Study of Non-CNS Drugs Becoming CNS Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Phytochemicals: Potential in Management of Climacteric Neurobiology
Current Pharmaceutical Design